Drug Name(s) RELENZA FDA Application No. (NDA) 021036 Active Ingredient(s) ZANAMIVIR Company GLAXOSMITHKLINE Original Approval or Tentative Approval Date July 26, 1999 Chemical Type 1New molecular entity (NME) Review Classification ... U.S. Food and Drug Administration, 1 day ago
2 images for "zanamivir"
Structure-Based Tetravalent Zanamivir with Potent Inhibitory Activity against Drug-Resistant Influenza Viruses
† CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Chaoyang District, Beijing 100101, China‡ National Engineering Research Center for Carbohydrate Synthesis, Jiangxi Normal ...Journal of Medicinal Chemistry, 2 weeks ago
New Cell Study Presents Groundbreaking Pre-Clinical Work: Developing Immune Therapy to Potentially Treat Serious Influenza A
Details Category: Antibodies Published on Friday, 22 July 2016 16:10 Hits: 9 MEDI8852 blocked all influenza A with unique binding properties Gaithersburg, MD, USA I July 21, 2016 I A paper published today by Cell presents pre-clinical work to ...PipelineReview, 2 days ago
Upcoming SlideShare Loading in … 5 1. DR. . firstname.lastname@example.org 2. INFLUENZA • Influenza is an acute respiratory tract infection caused by INFLUENZA VIRUS (which is of 3 types) : A, B, and C. 3. • At present three types of ...SlideShare.net, 5 days ago Influenza Remains A Threat Unaddressed: 500 Thousand People Hospitalized Every Year I2Mag, 2 months ago
Acute bronchitis, commonly known as a chest cold, is a short-term inflammation of lower respiratory tract affecting the air tubes (bronchi) of the lungs. The upper airways consisting of the nose and throat lead to the trachea or windpipe. The ...MedIndia, 3 weeks ago
Global Systemic Antiviral Pharmaceuticals Market Antiviral drugs are a class of medication that inhibits the development of infection causing viruses. Like antibiotics, specific antiviral drugs are used against specific viruses. As viruses share ...MyNewsDesk, 1 month ago Systemic Antiviral Pharmaceuticals Market - Global Industry Research 2016 to 2023 Press Release Ping, 1 month ago
/ 65(22);567575 Stacy L. Davlin, PhD1,2; Lenee Blanton, MPH1; Krista Kniss, MPH1; Desiree Mustaquim, MPH1; Sophie Smith, MPH1; Natalie Kramer1; Jessica Cohen, MPH1,2; Charisse Nitura Cummings, MPH1,3; Shikha Garg, MD1; Brendan Flannery, PhD1; ...Center for Disease Control and Prevention, 1 month ago
Abstract In order to better understand inflammation associated with influenza virus infection, we measured cell trafficking, via flow cytometry, to various tissues in the ferret model following infection with an A(H3N2) human seasonal influenza ...Plosone.org, 1 month ago
Patent Issued for Cap/Endo Dual Inhibitors and Their Use in the Treatment, Amelioration Or Prevention of a Viral Disease (USPTO 9359351)
By a News Reporter-Staff News Editor at -- According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Schulz-Gasch, Tanja (Ziefen, CH); Weikert, Robert ( Basel, CH); Neidhart, Werner ...Equities.com, 1 month ago Patent Issued for Prophylactic/Therapeutic Agent for Influenza Virus Infection (USPTO 9351949) 4 Traders, 1 month ago
Influenza A(H1N1)pdm09 virus exhibiting enhanced cross-resistance to oseltamivir and peramivir due to a dual H275Y/G147R substitution, Japan, March 2016
Takashita E, Ejima M, Itoh R, Miura M, Ohnishi A, Nishimura H, etal. A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Euro Surveill. 2014;19(1):20666.Eurosurveillance, 1 month ago
on your WebpageAdd Widget >Get your members hooked!